Selpercatinib Doubles Progression-Free Survival in RET-Mutated NSCLC
Selpercatinib doubled progression-free survival, increased response rate, and delayed pulmonary and physical deterioration in RET fusion-positive NSCLC.
Read More
Author: Teresa Sellinger
No Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer?
Active surveillance after neoadjuvant chemoradiotherapy may be an alternative to surgery for some with esophageal cancer.
Read More
Toripalimab/Chemotherapy Combo Improves Outcomes in Small Cell Lung Cancer
Toripalimab added to etoposide plus cisplatin or carboplatin improved survival in extensive-stage small cell lung cancer.
Read More
Addition of Pembrolizumab Improves pCR in Patients With Early-Stage High-Risk ER+/HER2- Breast Cancer
Pembrolizumab plus neoadjuvant chemotherapy in early-stage, high-risk ER+/HER2- breast cancer leads to a statistically significant increase in pathological complete response.
Read More
NICHE-3 Demonstrates Equally Impressive Results as NICHE-2
Nivolumab/relatlimab neoadjuvant treatment of deficient mismatch repair colon cancer shows impressive pathological response rates.
Read More
EV/Pembrolizumab Raises the Bar for OS in Metastatic Urothelial Cancer
First-line enfortumab vedotin (EV) plus pembrolizumab significantly improved survival in patients with locally advanced or metastatic urothelial cancer.
Read More
Is There Space for Physicians and Nurses to Both Claim ‘Doctor’?
The healthcare arena’s figurative boxing match between physicians and nurses over who besides...
Read More
Lifileucel Induces Durable Response in Heavily Pretreated Mucosal Melanoma
One-time lifileucel induces a strong and durable response in patients with advanced mucosal melanoma.
Read More
Perioperative Nivolumab Boosts Event-Free Survival in NSCLC
Perioperative chemotherapy plus nivolumab outperforms perioperative chemotherapy alone in patients with resectable non-small cell lung cancer.
Read More
LuPSMA & Enzalutamide: A Promising Combination
Enzalutamide plus LuPSMA has enhanced anticancer effects in prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.
Read More
Most Infants in ICU for RSV in 2022 Were Otherwise Healthy
Most infants admitted to the ICU with RSV do not have an underlying medical condition, but RSV remains a top cause of hospitalization in the first year of life.
Read More
Generative AI Poised to Revolutionize Healthcare Delivery & Life Sciences Research
Generative AI technology may transform healthcare delivery and life sciences productivity by improving patient outcomes and increasing clinical and medical research efficiency.
Read More
Durvalumab Climbs the MATTERHORN of Gastric Cancer
Durvalumab added to chemotherapy improves pathological complete response rate in the perioperative setting for patients with gastric cancer.
Read More
Atezolizumab Added to Chemo and PARP Inhibitor Shows No Benefit in Recurrent Ovarian Cancer
Atezolizumab plus chemotherapy and maintenance niraparib in late-relapsing recurrent chemotherapy-sensitive ovarian cancer does not significantly improve outcomes.
Read More
Benefit of Pembrolizumab in TNBC Remains At 5 Years
Pembrolizumab added to neoadjuvant and adjuvant chemotherapy improves event-free survival in patients with early triple-negative breast cancer (TNBC).
Read More
Explore, Connect, & Learn at the AAO 2023 Expo
Explore, connect, learn, relax and more at the AAO 2023 Expo. Follow PW for conference updates.
Read More
AAO Announces The Orbital 2023: Gold Rush Fundraising Event
AAO Announces The Orbital 2023: Gold Rush Fundraising Event, formerly the Orbital Gala.
Read More
Hispanic Patients Under-Represented in Liver Cancer Trials
Hispanic people have a disproportionately high incidence of liver cancer compared with other groups but are under-represented in Phase 3 trials for the disease.
Read More
Common Myths About Physician Retirement
The growing number of physicians approaching retirement age face a plethora of misinformation pertaining to retirement planning.
Read More
Improvements in PrEP Coverage Hinge on Braidwood Vs Becerra
Researchers report higher PrEP use and fewer insurance-related issues from 2019 to 2021, but the Braidwood versus Becerra case could impact these improvements.
Read More